akouos ak-otof

Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF at ASGCT

BOSTON, MASSACHUSSETTS — Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, presented nonclinical data at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting. The company gave two nonclinical presentations at the meeting: one that supports the…

Read More
akouos gene therapy hearing loss

Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer

BOSTON, MASSACHUSSETTS — Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer. Dr. Tward is a surgeon and a scientist with deep experience in genetics, genomics, gene delivery,…

Read More
akouos gene therapy hearing loss

Akouos Receives Orphan Drug Designation for AK-OTOF from European Medicines Agency

BOSTON, MASSACHUSSETTS — Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the company’s application for orphan drug designation for AK-OTOF, a…

Read More
akouos gene therapy hearing loss

Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss

BOSTON, MASSACHUSSETTS — Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for AK-OTOF, a gene therapy intended…

Read More
akouos blueprint genetics auditory neuropathy

Akouos and Blueprint Genetics Announce Resonate Program to Improve Access to Genetic Testing for Auditory Neuropathy

BOSTON, MASSACHUSSETTS – Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, and Blueprint Genetics, a Quest Diagnostics company, today announced the Resonate program. The program offers genetic testing to eligible individuals with auditory neuropathy at no cost to participants, their…

Read More
akouos gene therapy hearing loss

Akouos Announces Key Leadership Appointments

BOSTON, MASSACHUSSETTS — Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Sachiyo Minegishi as chief financial officer, effective today.   In addition, the company announced that Jennifer Wellman has been promoted to chief operating officer, from her prior…

Read More
akouos gene therapy hearing loss treatment

Akouos Provides Business Highlights and Reports Q2 2020 Financial Results

BOSTON, MASSACHUSSETTS — Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business highlights. “Our upsized initial public offering, which we completed in June,…

Read More
akouos gene therapy hearing loss treatment

Akouos Announces Expansion of Executive Team and Board of Directors

BOSTON, MASSACHUSSETTS — Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Alan Smith, Ph.D., as chief technology officer. In addition, the company announced that Saira Ramasastry has been appointed to its board of directors as…

Read More
akouos gene therapy hearing loss treatment

Akouos More Than Doubles Original IPO Goal, Raises $213M in First Day of Trading

BOSTON, MASSACHUSSETTS — After originally filing for an initial public offer (IPO) with the US Securities and Exchange Commission (SEC) earlier this month, eyeing a $100M IPO, gene therapy startup Akouos significantly exceeded its original expectations on Friday by raising $213M. The company sold 12.5 million shares for $17 each, above its anticipated range of…

Read More
akouos gene therapy hearing loss treatment

Akouos Files for $100M IPO to Accelerate Gene Therapy Hearing Loss Treatment Program

BOSTON, MASSACHUSSETTS – Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, has filed for an initial public offer (IPO) with the Securities and Exchange Commission, eyeing a $100M IPO. The filing comes barely 3 months after he company completed its Series B funding round, which raised $105M. The company’s…

Read More